Citigroup Maintains Sell on Core Laboratories, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Scott Gruber maintains a Sell rating on Core Laboratories (NYSE:CLB) and lowers the price target from $15 to $14.
October 31, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup analyst Scott Gruber maintains a Sell rating on Core Laboratories and lowers the price target from $15 to $14, indicating a bearish outlook.
The maintenance of a Sell rating and the reduction of the price target from $15 to $14 by Citigroup suggests a negative outlook on Core Laboratories' stock performance. This is likely to put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100